The Xpert<unk> /RIF is a cartridge-based nucleic acid amplification test (NAAT) for simultaneous rapid tuberculosis diagnosis and rapid antibiotic sensitivity test. It is an automated diagnostic test that can identify Mycobacterium tuberculosis <unk>  DNA and resistance to<unk> ampicin <unk> . It was co-developed by the laboratory of Professor David Alland at the University of Medicine and Dentistry of New Jersey (UMDNJ), Cepheid Inc. and Foundation for Innovative New Diagnostics, with additional financial support from the US National Institutes of Health (NIH). In December 2010, the World Health Organization (WHO) endorsed the Xpert<unk> /RIF for use in tuberculosis (TB) endemic countries. This followed 18 months of assessment of its field effectiveness in TB, MDR-TB and TB/HIV co-infection. The test may enable the diagnosis of TB in patients likely to be missed by traditional tests. According to the Centers for Disease Control and Prevention (CDC) in 2015, the Xpert<unk> /RIF test was "revolutionizing TB control by contributing to the rapid diagnosis of TB disease and drug resistance. The test simultaneously detects Mycobacterium tuberculosis complex <unk> C) and resistance to<unk> ampin <unk>  in less than 2 hours. In comparison, standard cultures can take 2 to 6 weeks for<unk> C to grow and conventional drug resistance tests can add 3 more weeks."
GeneXpert MTB/RIF
T-SPOT.TB
Throat culture
Viral culture
Mantoux test
Microscopic Observation Drug Susceptibility assay
Sputum culture
Malaria culture